Conversion from SMOFlipid® to Omegaven® as a salvage therapy for intestinal failure associated liver disease
Conversion to Omegaven® from SMOFlipid® reversed advanced IFALD in 63.6 % of patients. Response is less likely in children with synthetic liver dysfunction and clinically significant portal hypertension.
Authors
- Yaron Avitzur (ORCID: https://orcid.org/0000-0002-8072-5727)
- Glenda Courtney‐Martin (ORCID: https://orcid.org/0000-0001-6835-1366)
- Fernanda Takamatsu (ORCID: https://orcid.org/0000-0002-4302-0621)
- Stella Sabbatini (ORCID: https://orcid.org/0000-0002-2022-4840)
- Daniela Gattini (ORCID: https://orcid.org/0000-0001-8013-2350)
- Christina Belza (ORCID: https://orcid.org/0000-0001-6917-295X)
Institutions
- University of Toronto (CA)
- Hospital for Sick Children (CA)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100058
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00